Involvement of TNF-α converting enzyme in the development of psoriasis-like lesions in a mouse model.
TNF-α plays a crucial role in psoriasis; therefore, TNF inhibition has become a gold standard for the treatment of psoriasis. TNF-α is processed from a membrane-bound form by TNF-α converting enzyme (TACE) to soluble form, which exerts a number of biological activities. EGF receptor (EGFR) ligands, including heparin-binding EGF-like growth factor (HB-EGF), amphiregulin and transforming growth factor (TGF)-α are also TACE substrates and are psoriasis-associated growth factors. Vascular endothelial growth factor (VEGF), one of the downstream molecules of EGFR and TNF signaling, plays a key role in angiogenesis for developing psoriasis. In the present study, to assess the possible role of TACE in the pathogenesis of psoriasis, we investigated the involvement of TACE in TPA-induced psoriasis-like lesions in K5.Stat3C mice, which represent a mouse model of psoriasis. In this mouse model, TNF-α, amphiregulin, HB-EGF and TGF-α were significantly up-regulated in the skin lesions, similar to human psoriasis. Treatment of K5.Stat3C mice with TNF-α or EGFR inhibitors attenuated the skin lesions, suggesting the roles of TACE substrates in psoriasis. Furthermore, the skin lesions of K5.Stat3C mice showed down-regulation of tissue inhibitor of metalloproteinase-3, an endogenous inhibitor of TACE, and an increase in soluble TNF-α. A TACE inhibitor abrogated EGFR ligand-dependent keratinocyte proliferation and VEGF production in vitro, suggesting that TACE was involved in both epidermal hyperplasia and angiogenesis during psoriasis development. These results strongly suggest that TACE contributes to the development of psoriatic lesions through releasing two kinds of psoriasis mediators, TNF-α and EGFR ligands. Therefore, TACE could be a potential therapeutic target for the treatment of psoriasis.
Department of Dermatology, Kochi Medical School, Kochi University, Nankoku, Japan; Pharmacology Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan.
Kenji
K
Sato
Department of Dermatology, Kochi Medical School, Kochi University, Nankoku, Japan.
Mikiro
M
Takaishi
Pharmacology Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan.
Shota
S
Tokuoka
Department of Dermatology, Kochi Medical School, Kochi University, Nankoku, Japan.
Shigetoshi
S
Sano
D051722:ADAM Proteins / Q000378:metabolism*; D000072198:ADAM17 Protein; D066258:Amphiregulin; D000818:Animals; D004195:Disease Models, Animal; D066255:EGF Family of Proteins / Q000235:genetics; D005786:Gene Expression Regulation; D006801:Humans; D051379:Mice; D011565:Psoriasis / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D012867:Skin / Q000378:metabolism* / Q000473:pathology; D013755:Tetradecanoylphorbol Acetate / Q000031:analogs & derivatives; D016211:Transforming Growth Factor alpha / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics; D015854:Up-Regulation
C554292:12-O-tetradecanoylphorbol-1,3-acetate; D066258:Amphiregulin; C587849:Areg protein, mouse; D066255:EGF Family of Proteins; D016211:Transforming Growth Factor alpha; D014409:Tumor Necrosis Factor-alpha; D051722:ADAM Proteins; D000072198:ADAM17 Protein; C000606462:ADAM17 protein, human; C000606463:Adam17 protein, mouse; D013755:Tetradecanoylphorbol Acetate